Discontinuation of advanced therapy in inflammatory bowel disease: Updated evidence, guidelines, and personalized decision-making one year later
{{output}}
Therapy discontinuation in inflammatory bowel disease, particularly involving immunomodulators, biologics, and small molecules, remains a controversial and evolving topic. This letter reflects on developments following the publication by Meštrović et al, emp... ...
